Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Sipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after sipuleucel-T could modify immune and/or clinica...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Immunother Cancer
Κύριοι συγγραφείς: Sinha, Meenal, Zhang, Li, Subudhi, Sumit, Chen, Brandon, Marquez, Jaqueline, Liu, Eric V, Allaire, Kate, Cheung, Alexander, Ng, Sharon, Nguyen, Christopher, Friedlander, Terence W, Aggarwal, Rahul, Spitzer, Matthew, Allison, James P, Small, Eric J, Sharma, Padmanee, Fong, Lawrence
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BMJ Publishing Group 2021
Θέματα:
Clinical/Translational Cancer Immunotherapy
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8126308/
https://ncbi.nlm.nih.gov/pubmed/33986125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002254
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια